Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 15%
Hold 54%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is a diversified healthcare company with a strong presence in the United States, making up more than 60% of its revenue. With a focus on high-growth markets, the company's recent separation of its Lifesciences business allows for increased attention on its core medical and connected care units, while also returning cash to shareholders. Despite challenges in China, BD remains well-positioned for future growth and is committed to driving shareholder returns.

Bears say

Becton Dickinson is facing significant risks to delivering on its projected growth, including potential delays in achieving milestones related to the separation of its Biosciences and Diagnostics divisions and ongoing headwinds such as funding cuts and trade tensions. Additionally, competition in all segments, changes in healthcare delivery and reimbursement, and potential economic challenges could impact the company's operations. Despite potential upside from its recent business combination, BD may struggle to achieve its targeted high single-digit growth due to these factors.

BDX has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 15% recommend Buy, 54% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 13 analysts, BDX has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.